Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—Randox Toxicology has launched its Nitazenes Array, an immunoassay designed to detect a broad spectrum of nitazene analogs from a single sample. The array was developed using Randox’s proprietary biochip array technology and offers a rapid turnaround time. It is available on the company’s Evidence MultiStat platform.
December 2025—BD has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD Cor system. BD EBP offers a range of targets for enteric bacterial pathogens, including Salmonella spp., Campylobacter spp. (C. jejuni, C. coli), Shigella spp./enteroinvasive Escherichia coli, and Shiga toxin–producing E. coli. BD EBP Plus detects enterotoxigenic E. coli and heat-labile and heat-stable enterotoxin genes. The panel also identifies Plesiomonas shigelloides, Vibrio spp. (V. vulnificus, V. parahaemolyticus, V. cholerae), and Yersinia enterocolitica.
December 2025—Siemens Healthineers has introduced the Atellica DT 250 benchtop analyzer, to help identify substance use, monitor therapeutic and immunosuppressant drugs, and perform serum toxicology testing. It also offers automated specimen validity testing to detect substitution, adulteration, and dilution of urine samples. The analyzer can process 225 test results per hour and provide first results in as few as eight minutes. It features a menu of more than 65 immunoassays for use with urine, serum, and plasma samples and 10 open channels for customizable, user-defined testing.
December 2025—Primerdesign launched its Exsig Mag RapidBead Pro Extraction kit, a next-generation magnetic bead–based kit used to extract high-quality DNA and RNA from diverse sample types. The workflow reduces hands-on time compared to traditional methods and extracts DNA and RNA in less than 20 minutes.
December 2025—Bruker announced that its MALDI Biotyper CA system received expanded clearance from the FDA. The clearance includes the MBT Compass HT CA software and MBT Fast Shuttle US IVD as well as an expansion of the FDA-cleared reference library.
December 2025—Clear Labs announced at the Association for Molecular Pathology annual meeting (Boston, Nov. 11–15) its collaboration with Labcorp to automate PGDx kitted oncology NGS assays on the Clear Dx platform. Clear Labs says the collaboration aims to develop streamlined, end-to-end workflows that help laboratories improve efficiency, consistency, and throughput while laying the groundwork for future adoption across a range of genomic applications. This new workflow will expand Clear Labs’ infectious disease applications into oncology testing.
December 2025—Integrated DNA Technologies and Beckman Coulter Life Sciences are forming a strategic partnership to automate IDT’s customizable next-generation-sequencing assay solutions on Beckman Coulter’s newly launched Biomek i3 benchtop liquid handler. Through this partnership, the companies will work to automate IDT’s Archer FusionPlex and VariantPlex targeted sequencing assays and xGen Hybrid Capture workflows on the Biomek i3 system.
December 2025—HemoSonics has received FDA 510(k) clearance for expanded use of its Quantra hemostasis system with QStat cartridges in peripartum obstetric procedures. It is the first FDA-cleared viscoelastic testing platform for obstetric bleeding, according to a company press release. The system uses SEER (sonic estimation of elasticity via resonance) sonorheometry to measure the coagulation properties of a whole blood sample. It provides results in about 15 minutes.
December 2025—Diasorin has received FDA 510(k) clearance for the Simplexa COVID-19/Flu A/B and RSV Direct kit, a sample-to-answer test for the detection of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus directly from nasopharyngeal and nasal swab specimens. The kit runs on the Liaison MDX system and provides differential detection in about 45 minutes.
December 2025—The Journal of Clinical Microbiology has published an article describing ARUP Laboratories’ validation of a deep convolutional neural network to detect parasites in concentrated wet mounts of stool.
